Four Pralatrexate (PDX) Studies to Be Presented at the 50th Annual Meeting of the American Society of Hematology
10 Novembro 2008 - 12:17PM
Business Wire
Allos Therapeutics, Inc. (Nasdaq:ALTH), a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer, today announced that four
abstracts describing results from pralatrexate (PDX) studies have
been accepted for presentation at the 50th Annual Meeting of the
American Society of Hematology (ASH), to be held December 6 - 9,
2008, in San Francisco, California. The accepted abstracts describe
several clinical and pre-clinical pralatrexate studies, as follows:
�PROPEL: A Multi-center Phase 2 Open-label Study of Pralatrexate
(PDX) with Vitamin B12 and Folic Acid Supplementation in Patients
with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL).�
Owen O'Connor, M.D., Ph.D., Director of the Lymphoid Development
and Malignancy Program and Chief of the Lymphoma Service at the
Irving Comprehensive Cancer Center at Columbia University Medical
Center, is scheduled to report top line results from the PROPEL
trial in an oral presentation on Monday, December 8, 2008, during
the 7 a.m. to 9 a.m. (Pacific) oral presentations session in the
Moscone Center, 2005-2007-2018-2020 West. Dr. O�Connor is Principal
Investigator of the trial. �A Phase 1/2a Open-label Study of
Pralatrexate and Gemcitabine in Patients with Relapsed or
Refractory Lymphoproliferative Malignancies.� Steven Horwitz, M.D.,
Assistant Attending Physician, Lymphoma Service, Memorial
Sloan-Kettering Cancer Center, is scheduled to present interim data
from this study in a poster presentation on Saturday, December�6,
2008, from 5:30 p.m. to 7:30 p.m. (Pacific) in the Moscone Center,
Hall A. Dr. Horwitz is the Principal Investigator of the trial.
�Pralatrexate (PDX) is Active in Cutaneous T-Cell Lymphoma:
Preliminary Results of a Multi-center Dose-finding Trial.� Dr.
Horwitz is scheduled to present interim data from the Company�s
ongoing Phase 1 trial of pralatrexate in patients with relapsed or
refractory cutaneous T-cell lymphoma in a poster presentation on
Saturday, December�6, 2008, from 5:30 p.m. to 7:30 p.m. (Pacific)
in the Moscone Center, Hall A. �Pralatrexate (PDX) Complements the
Activity of the Proteasome Inhibitor Bortezomib (B) in In Vitro
Model of Lymphoid T-Cell Malignancies.� Dr. O�Connor is scheduled
to present results from a pre-clinical study of a combination of
pralatrexate and Velcade� (bortezomib) in a poster presentation on
Monday, December�8, 2008, from 5:30 p.m. to 7:30 p.m. (Pacific) in
the Moscone Center, Hall A. Copies of the abstracts can be found on
the ASH website at www.hematology.org/ and will be published in
Blood. About Allos Therapeutics, Inc. Allos Therapeutics is a
biopharmaceutical company focused on developing and commercializing
innovative small molecule drugs for the treatment of cancer.�The
Company's lead product candidate, pralatrexate (PDX), is a novel
antifolate currently under evaluation in a pivotal Phase 2 (PROPEL)
trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The PROPEL trial is being conducted under an agreement
reached with the U.S. Food and Drug Administration under its
special protocol assessment, or SPA process. The Company is also
investigating pralatrexate in patients with non-small cell lung
cancer, bladder cancer and a range of lymphoma sub-types.�The
Company's other product candidate�is RH1, a targeted
chemotherapeutic agent currently being evaluated in a Phase 1 trial
in patients with advanced solid tumors or non-Hodgkin�s lymphoma
(NHL). The Company currently retains exclusive worldwide rights to
pralatrexate and RH1 for all indications. For additional
information, please visit the Company�s website at www.allos.com.
Safe Harbor Statement The anticipated presentations may contain
forward-looking statements that involve significant risks and
uncertainties, including those to be discussed in the presentation
and others that can be found in the "Risk Factors" section of the
Company's Form 10-K for the year ended December 31, 2007 and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics, Inc.